ArticleActa ophthalmologica2025
Juvenile idiopathic arthritis during 20 years in Sweden: Characteristics of children, therapy interventions, occurrence of uveitis and ocular complications.
Article in Acta ophthalmologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical characteristics and factors associated with uveitis in juvenile idiopathic arthritis: a long-term single-center experience.International ophthalmology · 2026Article
- Incidence and Predictors of Ocular Complications in Pediatric-Onset Uveitis: Data from the AIDA Network Uveitis Registry.Ophthalmology and therapy · 2025Article
- Juvenile idiopathic arthritis during 20 years in Sweden: Characteristics of children, therapy interventions, occurrence of uveitis and ocular complications.Acta ophthalmologica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo assess and compare the characteristics, therapy interventions, occurrence of uveitis and ocular complications in children with juvenile idiopathic arthritis (JIA) screened and examined for uveitis in Gothenburg, Sweden, over 20 years. Biological immunomodulatory treatment was increasingly used during the second half of the over 20 years.
methodsData were retrospectively collected from children with JIA examined for uveitis at the Queen Silvia Children's Hospital between 2012 and 2021. These data were compared with those from a previously published study of children (the first cohort) screened between 2002 and 2011 in the same setting.
resultsThe first 10-year cohort (2002-2011) included 299 children, while the second cohort (2012-2021) included 253 children. The median age at JIA diagnosis was 5 years (range: 1-15 years) in both cohorts (p = 0.72), and girls were overrepresented in both groups, 68.9% and 72.7%, respectively (p = 0.32). Oligoarthritis was less frequent in the first cohort than in the second, 57.5% versus 73.9% (p < 0.001). The presence of anti-nuclear antibodies (ANAs) was similar between the cohorts, 57.6% versus 57.9% (p = 0.95). Uveitis occurred less frequently in the first cohort, 10.7% versus 17.0% in the second (p = 0.032). However, uveitis children had (not significantly) more ocular complications in the first cohort, 46.9% versus 34.9% in the second (p = 0.34) and complications were more often affecting both eyes, 73.3% versus 40.0% (p = 0.14). Systemic treatments, particularly biological immunomodulatory therapies, were less commonly used in the first cohort, 24.4% versus 42.7% in the second cohort (p < 0.001).
conclusionOver 20 years, we observed a higher occurrence of uveitis in children with JIA in the second 10-year cohort. However, despite being statistically insignificant, we found fewer ocular complications, and less frequent in both eyes. This may indicate a beneficial effect of the increased use of biological immunomodulatory therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.